Diurnal lipid and lipoprotein profiles with bezafibrate and clofibrate in healthy volunteers.
Diurnal lipid and lipoprotein profiles were measured in 28 healthy volunteers after 10-day treatment periods with placebo, bezafibrate (200 mg 3-times daily) or clofibrate (500 mg 3-times daily) in a double-blind, parallel trial. The two drugs lowered fasting triglyceride and cholesterol levels (p less than or equal to 0.05 for cholesterol with bezafibrate vs placebo). Diurnal triglyceride profiles were lowest with bezafibrate due to lowest fasting triglycerides. Alimentary lipaemia with placebo was mild and due to increased VLDL-triglycerides, while the other lipoprotein lipids and total plasma cholesterol remained virtually unchanged during the day. Bezafibrate (half-life 2 hours) and clofibrate (half-life 15 hours) gave similar diurnal triglyceride patterns. The diurnal values were dependent on the fasting values. Changes in the cholesterol/phospholipid ratio during the day may be related to altered post-prandial composition of HDL.
D000328:Adult; D001629:Bezafibrate / Q000097:blood / Q000494:pharmacology*; D002784:Cholesterol / Q000097:blood; D002940:Circadian Rhythm; D002994:Clofibrate / Q000097:blood / Q000494:pharmacology*; D006207:Half-Life; D006801:Humans; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D014280:Triglycerides / Q000097:blood
D008055:Lipids; D008074:Lipoproteins; D014280:Triglycerides; D002784:Cholesterol; D002994:Clofibrate; D001629:Bezafibrate